8-K: 23andMe Completes $305 Million Asset Sale to Affiliate Amidst Chapter 11 Proceedings

23andMe Holding Co. has completed the sale of substantially all of its assets, including its Personal Genome Service and Research Services business lines, to TTAM Research Institute, an affiliate of co-founder Anne Wojcicki, for $305 million in cash, while remaining in Chapter 11 bankruptcy.

Summary

• 23andMe Holding Co. (the Company) and its subsidiaries (the Debtors) completed the sale of substantially all of their assets to TTAM Research Institute for $305.0 million in cash, plus the assumption of certain liabilities and cure payments.
• The acquired assets include the Personal Genome Service (PGS) and Research Services business lines.
• TTAM Research Institute is a California nonprofit public benefit corporation affiliated with Anne Wojcicki, the Company's co-founder, former chief executive officer, and current Board member.
• The transaction was consummated on July 14, 2025, following court approval on June 27, 2025.
• In connection with the transaction, the Debtors fully repaid all outstanding indebtedness and terminated commitments under their Senior Secured, Super-Priority Debtor-in-Possession Loan and Security Agreement with JMB Capital Partners Lending, LLC.
• The Company's Chapter 11 bankruptcy cases, initiated on March 23, 2025, remain pending.
• TTAM Research Institute also agreed to serve as a stalking horse sponsor for a Chapter 11 plan to acquire the Company's telehealth services business (Lemonaid Health, Inc.) for an aggregate purchase price of $2.5 million, which was excluded from the primary asset sale.
• The financial impact of the transaction will be reflected in the Company's monthly operating reports starting July 2025.

Sentiment

Score: 2

Explanation: The sentiment is very negative due to the ongoing Chapter 11 bankruptcy, the sale of substantially all assets, and explicit warnings about the highly speculative and risky nature of the common stock, with uncertain recovery for shareholders. While the debt repayment and asset sale completion are steps in the bankruptcy process, they are outcomes of severe financial distress.

Positives

• The Company successfully completed the sale of its core assets, securing $305.0 million in cash.
• All outstanding indebtedness under the Senior Secured, Super-Priority Debtor-in-Possession Loan was repaid in full, terminating associated commitments.
• The Personal Genome Service (PGS) and Research Services business lines will continue to operate under TTAM Research Institute, ensuring continuity for customers.
• TTAM Research Institute has committed to providing customers with choice and transparency regarding their data, including the option to change their decision on research participation.

Negatives

• The Company remains in Chapter 11 bankruptcy proceedings, indicating ongoing financial distress.
• The sale involves 'substantially all' of the Debtors' assets, signifying a significant divestiture of the Company's operations.
• Trading in the Company's Class A common stock is explicitly cautioned as highly speculative and posing substantial risks, with prices potentially bearing little or no relationship to actual recovery for shareholders.
• There is no assurance of liquidity, an active trading market, or predictable prices for the Company's common stock on the OTC Pink Market.

Risks

• Risks and uncertainties relating to the Chapter 11 Cases, including obtaining Court approval for motions, the effects on the Company and various constituents, and the general outcome of the cases.
• Uncertainty regarding the length of time the Company will operate under Chapter 11.
• Risks associated with any third-party motions in the Chapter 11 Cases.
• Potential adverse effects of the Chapter 11 Cases on the Company's liquidity or results of operations.
• Increased legal and other professional costs necessary to execute the Company's reorganization.
• Uncertainty whether the Company will emerge, in whole or in part, from the Chapter 11 Cases as a going concern.
• Risks related to the trading price and volatility of the Common Stock.
• Uncertainty regarding the continuation of trading of the Common Stock on the OTC Pink Market, including whether broker-dealers will continue to provide public quotes, whether trading volume will be sufficient for an efficient market, and whether quotes will continue in the future.

Future Outlook

The Company expects to provide additional information regarding the distribution of proceeds from the transaction at a subsequent date. The Chapter 11 Cases remain pending, and the Company's ability to emerge, in whole or in part, as a going concern is uncertain. Trading of the common stock on the OTC Pink Market is subject to risks regarding continued public quotes, sufficient trading volume, and future market presence.

Management Comments

• Joseph Selsavage is listed as Interim Chief Executive Officer, and Chief Financial and Accounting Officer.
• TTAM Research Institute, led by Anne Wojcicki, is committed to providing customers with choice and transparency with their data, including the option to change their decision on whether to participate in research.

Industry Context

This announcement reflects a significant restructuring event for 23andMe, a genetics-led consumer healthcare company, as it navigates Chapter 11 bankruptcy. The sale of its core Personal Genome Service and Research Services business lines to a related non-profit entity indicates a strategic shift and divestiture of its primary commercial operations, while retaining a telehealth business for potential future sale. This move highlights the challenges faced by some direct-to-consumer genetic testing companies in achieving sustainable profitability and the increasing trend of consolidation or restructuring within the broader consumer healthcare and genomics sectors.

Comparison to Industry Standards

• NA

Legal Proceedings

• The Company and certain subsidiaries are currently undergoing Chapter 11 bankruptcy proceedings in the United States Bankruptcy Court for the Eastern District of Missouri (the Chapter 11 Cases).

Related Party Transactions

• The asset purchase agreement was entered into with TTAM Research Institute, which is an affiliate of Anne Wojcicki, the Company's co-founder, former chief executive officer, and current member of the Company's Board of Directors.

Stakeholder Impact

• Shareholders: Highly negative impact, as common stock is deemed highly speculative with substantial risks and uncertain recovery in the Chapter 11 Cases.
• Creditors: Positive impact for the DIP lender (JMB Capital Partners Lending, LLC) as their outstanding indebtedness was repaid in full. Other creditors will await distribution of proceeds from the asset sale.
• Customers: The Personal Genome Service (PGS) and Research Services business lines will continue to operate under TTAM Research Institute, with a commitment to data choice and transparency, suggesting continuity for customers of these services.
• Employees: Not explicitly detailed, but the continuation of business lines under TTAM suggests some level of continuity for employees associated with those operations.

Next Steps

• The Company expects to provide additional information regarding the distribution of proceeds from the transaction at a subsequent date.
• The Chapter 11 Cases remain pending, with ongoing court proceedings and potential third-party motions.
• TTAM Research Institute will serve as a stalking horse sponsor for a Chapter 11 plan to acquire the telehealth services business (Lemonaid Health, Inc.) for $2.5 million.

Key Dates

Recommendation

Keywords

23andMe, Chapter 11, Bankruptcy, Asset Sale, TTAM Research Institute, Anne Wojcicki, Personal Genome Service, Research Services, Debtor-in-Possession Loan, Telehealth, Lemonaid Health, SEC Filing, Form 8-K, Corporate Restructuring, Genetic Testing, Consumer Healthcare